Jennifer Ceynar Moen
Nurse Practitioner · Bismarck, NDNPI 1649298720
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 99 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 22.3% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in ND with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 99 payments — averaging $22.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$486
- Biogen$413
- EMD Serono, Inc.$287
- Lundbeck LLC$123
- Nevro Corp.$99
- Pfizer$89
- plus $681 from 25 others
What the payments were for
- Food & beverage$2,179100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 31 | $486 |
| Biogen | 8 | $413 |
| EMD Serono, Inc. | 8 | $287 |
| Lundbeck LLC | 6 | $123 |
| Nevro Corp. | 1 | $99 |
| Pfizer | 6 | $89 |
| AstraZeneca | 5 | $77 |
| Johnson & Johnson | 3 | $48 |
| Amgen | 3 | $47 |
| UCB, Inc. | 2 | $41 |
| Mallinckrodt Hospital Products Inc. | 2 | $40 |
| Boston Scientific | 1 | $39 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $38 |
| Springworks Therapeutics, Inc. | 2 | $36 |
| Acadia Pharmaceuticals Inc | 2 | $35 |
| Medtronic | 1 | $30 |
| Piramal Critical Care | 1 | $28 |
| Radius Health, Inc. | 1 | $24 |
| Sanofi | 1 | $18 |
| Neurocrine Biosciences, Inc. | 1 | $18 |
| Novartis | 1 | $17 |
| Kyowa Kirin, Inc. | 1 | $17 |
| Pharming Healthcare, Inc. | 1 | $17 |
| Bristol Myers Squibb | 1 | $16 |
| ANI Pharmaceuticals, Inc. | 1 | $15 |
| Amylyx Pharmaceuticals, Inc. | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
| Averitas Pharma Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $13 |
| Argenx US, Inc. | 1 | $13 |
| Ultragenyx Pharmaceutical Inc. | 1 | $13 |
How this compares
$2,179 in reported general payments places this provider in the 90th percentile of 455 nurse practitioner providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Emgality PenGalcanezumab-Gnlm | 50 | $40,586 |
| Aimovig AutoinjectorErenumab-Aooe | 51 | $38,234 |
| QuliptaAtogepant | 30 | $35,732 |
| UbrelvyUbrogepant | 34 | $33,342 |
| Nurtec OdtRimegepant Sulfate | 23 | $24,725 |
| Lacosamide | 76 | $11,939 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 196 | $8,813 |
| BrilintaTicagrelor | 17 | $7,298 |
| Levetiracetam | 251 | $6,761 |
| Carbamazepine ErCarbamazepine | 24 | $4,275 |
| Divalproex Sodium ErDivalproex Sodium | 30 | $3,307 |
| Duloxetine Hcl | 116 | $2,990 |
| Propranolol Hcl ErPropranolol Hcl | 53 | $2,767 |
| Memantine Hcl | 131 | $2,702 |
| DilantinPhenytoin Sodium Extended | 16 | $2,422 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieQulipta, Ubrelvy | $486 | $69,07464 claims |
| PfizerNurtec Odt, Dilantin | $89 | $27,14739 claims |
| AstraZenecaBrilinta | $77 | $7,29817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 455 nurse practitioner providers in North Dakota.
Other nurse practitioner in Bismarck
- Lisa ClairmontBismarck$15K
- McKinzie NussBismarck$7K
- Paula MochBismarck$5K
- Trina KaiserBismarck$5K
- Cassie HoltBismarck$5K
- Katherine CarvellBismarck$5K
- Shih Ru MartinBismarck$5K
- Janel OlsonBismarck$4K
- Mallorie EmoryBismarck$3K
- Kayla CoferBismarck$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.